Tagged with Data

Europe Janssen’s Cyril Titeux highlights the commonalities and challenges within his 31-country portfolio, his hopes and expectations for the evolution of market access in the region, and some of the key industry trends emerging from the COVID-19 pandemic.   I foresee a renewed and increased focus on prevention [post-COVID], especially for…

Switzerland CEO Tero Silvola introduces BC Platforms’ powerful data and technology platform for personalized medicine and drug development and the ‘infinity loop’ between the interconnected sectors of healthcare and life sciences that the company serves. Silvola also highlights how BC Platforms leverages the Swiss innovation ecosystem and why the next five…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Singapore Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.   We…

Switzerland Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology to significantly reduce the drug development timeline. Clinerion uses Big Data analytics technologies to help hospitals, pharmaceutical companies and research…

USA Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing access and driving down costs in the process.   2020 has been an exceptionally turbulent year – especially for the…

Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’.   Data is the new oil, but biomedical data – despite its abundance…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while enabling us to maintain a culture of innovation and growth.   Are social distancing requirements causing the life science industry to return to an inward-looking culture of secrecy?…

Data New approaches to pharma sales: Marrying data analytics with the art of personal engagement   The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume,…

China I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in China (Club Santé Chine). I would like to share here some learnings and personal thoughts.   One of the consequences…

Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future.   Imagine if we invested billions in epidemiological surveillance…

Global With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to allay these costs has grown. However, experts are split as to the true potential of digital tools to reduce clinical development outlay and provide better patient outcomes in the…